Silicon Investor (SI) -- The First Internet Community

STOCKTALK

We've detected that you're using an ad content blocking browser plug-in or feature. Ads provide a critical source of revenue to the continued operation of Silicon Investor. We ask that you disable ad blocking while on Silicon Investor in the best interests of our community. If you are not using an ad blocker but are still receiving this message, make sure your browser's tracking protection is set to the 'standard' level.

Biotech / Medical : ARIAD Pharmaceuticals -- Ignore unavailable to you. Want to Upgrade?

To: tom pope who wrote (3229)	2/22/2014 7:50:07 PM
From: tejek	Respond to of 4474

AF is unrelenting in his criticism of ARIA, and especially Harvey Berger. The virulence makes it sound personal. I would be tempted to discount his views - EXCEPT he got it right last summer when he foretold that pona had problems. Remember "dirty drug"? There is no question that AF is a pretty cynical person and it doesn't take much for him to get angry. Maybe he's had a run in with Berger. I have to say that he is pulling his punch when it comes to ARIA..........when he is absolutely certain of his position, he usually goes for the jugular..........see his comments on Mannkind and other biotechs he thinks are scams.

To: tom pope who wrote (3229)	2/23/2014 1:21:29 AM
From: Zohar_Power	Respond to of 4474

If ponatinib was a "dirty drug" it would not be on the market. Statements like that are unprofessional, unscientific and likely slanderous. AF has discredited himself with these kind of kooky tirades, based on what appears to be personal animosity. Evidently the leading medical experts on this drug have a much more favorable opinion.